IS5321A - Bætt mótefni gegn IgE og aðferð til endurbóta á fjölpeptíðum - Google Patents

Bætt mótefni gegn IgE og aðferð til endurbóta á fjölpeptíðum

Info

Publication number
IS5321A
IS5321A IS5321A IS5321A IS5321A IS 5321 A IS5321 A IS 5321A IS 5321 A IS5321 A IS 5321A IS 5321 A IS5321 A IS 5321A IS 5321 A IS5321 A IS 5321A
Authority
IS
Iceland
Prior art keywords
enhancement method
ige antibodies
polypeptide
improved
polypeptide enhancement
Prior art date
Application number
IS5321A
Other languages
English (en)
Other versions
IS2039B (is
Inventor
B. Lowman Henry
G. Presta Leonard
M. Jardieu Paula
Lowe John
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of IS5321A publication Critical patent/IS5321A/is
Publication of IS2039B publication Critical patent/IS2039B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
IS5321A 1997-07-02 1999-12-23 Bætt mótefni gegn IgE og aðferð til endurbóta á fjölpeptíðum IS2039B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/887,352 US5994511A (en) 1997-07-02 1997-07-02 Anti-IgE antibodies and methods of improving polypeptides
PCT/US1998/013410 WO1999001556A2 (en) 1997-07-02 1998-06-30 IMPROVED ANTI-IgE ANTIBODIES AND METHOD OF IMPROVING POLYPEPTIDES

Publications (2)

Publication Number Publication Date
IS5321A true IS5321A (is) 1999-12-23
IS2039B IS2039B (is) 2005-08-15

Family

ID=25390964

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5321A IS2039B (is) 1997-07-02 1999-12-23 Bætt mótefni gegn IgE og aðferð til endurbóta á fjölpeptíðum

Country Status (29)

Country Link
US (4) US5994511A (is)
EP (1) EP0996728B1 (is)
JP (2) JP4286327B2 (is)
KR (1) KR100547538B1 (is)
CN (1) CN1260357C (is)
AR (2) AR013169A1 (is)
AT (1) ATE253116T1 (is)
AU (1) AU741115B2 (is)
BR (2) BRPI9810654C1 (is)
CA (1) CA2295540C (is)
CZ (1) CZ300724B6 (is)
DE (1) DE69819332T2 (is)
DK (1) DK0996728T3 (is)
ES (1) ES2210778T3 (is)
HK (1) HK1027833A1 (is)
HU (1) HU228845B1 (is)
IL (2) IL133973A0 (is)
IS (1) IS2039B (is)
NO (1) NO324992B1 (is)
NZ (1) NZ501842A (is)
PL (1) PL194562B1 (is)
PT (1) PT996728E (is)
RO (1) RO120848B1 (is)
RU (1) RU2242515C2 (is)
SK (1) SK284395B6 (is)
TR (1) TR200000206T2 (is)
TW (2) TWI233946B (is)
WO (1) WO1999001556A2 (is)
ZA (1) ZA985500B (is)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20040146507A1 (en) * 1996-11-27 2004-07-29 Genentech, Inc. Antibody mutants
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7759133B2 (en) * 1998-12-22 2010-07-20 Alk-Abello A/S Method of detecting and/or quantifying a specific IgE antibody in a liquid sample
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US20020019009A1 (en) * 1999-12-09 2002-02-14 Roggen Erwin Ludo High throughput screening (HTS) assays
WO2001044441A1 (en) * 1999-12-14 2001-06-21 Thermo Biostar, Inc. Stabilizing diluent for polypeptides and antigens
JP2003520828A (ja) * 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
US7018801B2 (en) * 2000-02-11 2006-03-28 Board Of Regents, The University Of Texas System Selection of peptides with antibody-like properties
US20030143638A1 (en) * 2000-04-07 2003-07-31 Mahito Hirai Antibody/carrier complex, process for producing the same, method of controlling antigen-antibody reaction by using the same and immunoassay method
US7176037B2 (en) * 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US6951947B2 (en) * 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
DE60143544D1 (de) * 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002240751A1 (en) * 2001-03-09 2002-09-24 William Herman Targeted ligands
US6966992B2 (en) * 2001-03-19 2005-11-22 Akzo Nobel Nv Method of purification of molecules using unbranched terminal alkyldiols
AU2002327171A1 (en) * 2001-05-01 2003-01-02 Medimmune, Inc. Crystals and structure of synagis fab
AU2002316887A1 (en) * 2001-05-03 2002-11-18 Novartis Ag Anti-ige antibody to treat ocular allergies
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2447791A1 (en) * 2001-06-13 2002-12-19 Neslihan Delacruz Methods of culturing animal cells and polypeptide production in animal cells
US20030073249A1 (en) * 2001-07-07 2003-04-17 Lee Duen Allergen detection chip
JP2003137804A (ja) * 2001-10-31 2003-05-14 Morinaga Milk Ind Co Ltd インターロイキン−１８誘導剤
US7179798B2 (en) * 2001-11-16 2007-02-20 Russell R. Roby Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
JP4063769B2 (ja) * 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
EP1461001A4 (en) * 2002-01-03 2010-03-31 Scripps Research Inst EPITOPE ASSOCIATED WITH CANCER
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
US20050142539A1 (en) * 2002-01-14 2005-06-30 William Herman Targeted ligands
AU2003210802B2 (en) * 2002-02-05 2009-09-10 Genentech Inc. Protein purification
DK1495055T3 (da) * 2002-04-18 2013-11-11 Genencor Int Produktion af funktionelle antistoffer i filamentøse svampe
EP1532162B1 (en) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
ES2551682T3 (es) * 2002-11-08 2015-11-23 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
US20060034833A1 (en) * 2002-11-08 2006-02-16 Els Beirnaert Single domain antibodies directed against interferron-gamma and uses therefor
JP2006520584A (ja) * 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
AU2003286004A1 (en) * 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP2407485B1 (en) * 2003-02-01 2016-01-27 Tanox, Inc. High affinity anti-human IgE antibodies
US20060234296A1 (en) * 2003-02-01 2006-10-19 Sanjaya Singh Method for generating high affinity antibodies
DE602004029868D1 (de) * 2003-03-05 2010-12-16 Chemo Sero Therapeut Res Inst Verfahren zur herstellung eines heterologen proteins in e. coli
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2523912A1 (en) * 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
EP1670812A2 (en) * 2003-09-05 2006-06-21 The Scripps Research Institute Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular diseases
WO2005023831A1 (en) * 2003-09-05 2005-03-17 The Scripps Research Institute Detection of cholesterol ozonation products
CA2540165A1 (en) * 2003-10-08 2005-04-21 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
EP1688432B1 (en) 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Igm high concentration stabilized solution
WO2005088308A2 (en) * 2004-03-12 2005-09-22 The Scripps Research Institute Fluorescent signal emitting live cell biosensor molecules and dyes for detection and quantification of protein activities
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
EP1733234B1 (en) * 2004-04-06 2011-09-14 Mount Sinai School Of Medicine Methods of determining allergen response using microarray immunoassay techinques
WO2005105106A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of macular degeneration
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US7604947B2 (en) * 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
RU2442571C2 (ru) 2004-07-23 2012-02-20 Дженентек, Инк. Кристаллизация антител или их фрагментов
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
CA2583011A1 (en) * 2004-10-05 2006-04-20 Tanox, Inc. Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
SV2008002394A (es) * 2005-01-28 2008-02-08 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido ref. ahn- 072sv
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
EP2336327A1 (en) 2005-03-25 2011-06-22 National Research Council of Canada Method for isolation of soluble polypeptides
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
WO2007032804A2 (en) * 2005-06-30 2007-03-22 Clifford Risk Novel uses for anti-ige therapy
EP2298815B1 (en) 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
WO2008020827A2 (en) * 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
US8137670B2 (en) * 2005-09-29 2012-03-20 Medimmune, Llc Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
CN101062949B (zh) * 2006-04-26 2011-07-27 上海抗体药物国家工程研究中心有限公司 重组抗人IgE单克隆抗体及其制备方法和用途
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
KR20090069330A (ko) * 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
JP2010519194A (ja) * 2007-02-15 2010-06-03 アストラゼネカ・アクチエボラーグ ＩｇＥ分子に対する結合要素
AR065368A1 (es) * 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
ES2478242T3 (es) 2007-03-22 2014-07-21 Genentech, Inc. Anticuerpos anti IgE apoptóticos que se unen con el IgE unido a membrana
GT200800034A (es) * 2007-04-02 2010-03-16 Anticuerpos anti-ige
WO2008119566A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
WO2008119567A2 (en) † 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
JP2010524467A (ja) * 2007-04-16 2010-07-22 モメンタ ファーマシューティカルズ インコーポレイテッド 規定の糖タンパク質産物および関連の方法
WO2008141044A2 (en) * 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
SI2215117T2 (en) 2007-10-30 2018-04-30 Genentech, Inc. Purification of the antibody by cation exchange chromatography
EP2238156B1 (en) * 2008-01-29 2014-10-01 Ablynx N.V. Methods to stabilize proteins and polypeptides
WO2009126944A1 (en) * 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
IT1391559B1 (it) * 2008-09-01 2012-01-11 Lofarma Spa Allergoidi derivati da allergeni
PT3190128T (pt) 2008-09-17 2019-02-07 Xencor Inc Composições e métodos para tratar distúrbios mediados pela ige
CN104740631B (zh) 2008-10-29 2019-04-16 阿布林克斯公司 单域抗原结合性分子的制剂
JP6113404B2 (ja) 2008-10-29 2017-04-12 アブリンクス エン．ヴェー． 単一ドメイン抗原結合分子の精製方法
CA2743487A1 (en) * 2008-11-13 2010-05-20 Emergent Product Development Seattle, Llc Cd37 immunotherapeutic combination therapies and uses thereof
EP2373689A1 (en) 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
US20100190963A1 (en) 2008-12-16 2010-07-29 Millipore Corporation Stirred Tank Reactor And Method
BRPI1006519A2 (pt) * 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
WO2011028753A1 (en) 2009-09-01 2011-03-10 Genentech, Inc. Enhanced protein purification through a modified protein a elution
JP6139885B2 (ja) 2009-10-26 2017-05-31 ジェネンテック， インコーポレイテッド 治療的抗ＩｇＥ抗体に特異的な抗体を検出するためのアッセイ及びアナフィラキシーにおけるそれらの使用
EP2542257B1 (en) 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
KR20120138241A (ko) * 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체
EP3513810A1 (en) 2010-03-22 2019-07-24 F. Hoffmann-La Roche AG Compositions and methods useful for stabilizing protein- containing formulations
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX2012011648A (es) 2010-04-07 2012-11-29 Momenta Pharmaceuticals Inc Glicanos de alta manosa.
BR112012028977B1 (pt) 2010-05-17 2020-05-05 Emd Millipore Corp método de purificação de biomolécula por meio de polímeros estímulo-responsivos
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012064627A2 (en) 2010-11-08 2012-05-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
US9170249B2 (en) 2011-03-12 2015-10-27 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing N-glycans in glycoprotein products
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
CA2835242A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
EP2809684A1 (en) 2012-01-31 2014-12-10 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
WO2013120973A1 (en) * 2012-02-15 2013-08-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of producing high-affinity antibodies
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
RU2711089C2 (ru) 2012-05-18 2020-01-15 Дженентек, Инк. Высококонцентрированные составы моноклональных антител
WO2013181577A2 (en) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to omalizumab
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014041544A1 (en) 2012-09-12 2014-03-20 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
AU2014343636A1 (en) 2013-11-04 2016-06-02 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
WO2015073740A2 (en) 2013-11-13 2015-05-21 Genentech, Inc. Assisted manual injector devices and methods
CA2944712A1 (en) * 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
PT3157951T (pt) * 2014-06-17 2020-08-24 Academia Sinica Anticorpos anti-ige humanizados que reticulam cd23 em linfócitos b, mas não sensibilizam mastócitos
KR102355306B1 (ko) 2014-07-09 2022-01-24 제넨테크, 인크. 세포 은행의 해동 회수를 개선하는 ph 조정
AU2015292326A1 (en) 2014-07-24 2017-02-23 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
WO2016164920A1 (en) 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP4434516A2 (en) 2016-07-18 2024-09-25 Ramot at Tel-Aviv University Ltd. Modular platform for targeted therapeutics
EP3538558A4 (en) * 2016-11-09 2020-07-15 North Carolina State University TREATMENT OF ALLERGIC DISEASES WITH A CHIMERAL PROTEIN
KR102579836B1 (ko) 2016-12-22 2023-09-15 제넨테크, 인크. 동결건조된 폴리펩타이드의 재구성 시간을 감소시키기 위한 방법 및 제제
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
EP4296680A3 (en) * 2017-08-10 2024-03-20 Grifols Diagnostic Solutions Inc. An oligomerization tag comprising an immunoglobulin fc region and a polyhis domain
RU2758092C1 (ru) * 2018-02-01 2021-10-26 Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. АНТИТЕЛО К IL-4Rα И ЕГО ПРИМЕНЕНИЕ
CA3226165A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
KR20230042030A (ko) * 2020-07-10 2023-03-27 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 항-IgE 조작된 항체 및 이의 적용
CN111879923A (zh) * 2020-08-06 2020-11-03 深圳科隆生物新材料有限公司 一种可消除hama效应的试剂盒

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6031471B2 (ja) * 1978-07-21 1985-07-22 協和醗酵工業株式会社 グリセロ−ル酸化酵素およびその製法
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
WO1992009690A2 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US6329509B1 (en) * 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
DE122006000006I2 (de) * 1991-08-14 2011-06-16 Genentech Inc Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
ES2241710T3 (es) * 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
CA2372813A1 (en) * 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
WO1994020533A1 (en) 1993-03-11 1994-09-15 Tanox Biosystems, Inc. PEPTIDES REPRESENTING ANTIGENIC EPITOPES OF IgE PRESENT ON B CELL BUT NOT BASOPHIL SURFACE
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5561053A (en) 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE265861T1 (de) * 1995-08-17 2004-05-15 Protein Design Labs Inc Antikörper gegen l-selectin zur vorbeugung von multiplem organversagen und akuter organschädigung
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides

Also Published As

Publication number Publication date
TWI233946B (en) 2005-06-11
BRPI9810654C1 (pt) 2021-05-25
WO1999001556A3 (en) 1999-04-22
IL133973A (en) 2006-12-10
EP0996728A2 (en) 2000-05-03
PT996728E (pt) 2004-03-31
KR20010014422A (ko) 2001-02-26
NO996551L (no) 2000-03-01
CN1268176A (zh) 2000-09-27
JP2009055902A (ja) 2009-03-19
CA2295540A1 (en) 1999-01-14
HUP0002474A3 (en) 2003-03-28
EP0996728B1 (en) 2003-10-29
CZ300724B6 (cs) 2009-07-29
BR9810654B8 (pt) 2013-02-19
AR060038A2 (es) 2008-05-21
HK1027833A1 (en) 2001-01-23
BR9810654B1 (pt) 2013-01-08
US20030149244A1 (en) 2003-08-07
CN1260357C (zh) 2006-06-21
TW570976B (en) 2004-01-11
AU8270198A (en) 1999-01-25
US6761889B2 (en) 2004-07-13
AU741115B2 (en) 2001-11-22
KR100547538B1 (ko) 2006-01-31
SK284395B6 (sk) 2005-03-04
DE69819332T2 (de) 2004-07-15
NO996551D0 (no) 1999-12-29
US5994511A (en) 1999-11-30
DE69819332D1 (de) 2003-12-04
DK0996728T3 (da) 2004-02-23
IL133973A0 (en) 2001-04-30
IS2039B (is) 2005-08-15
ES2210778T3 (es) 2004-07-01
CA2295540C (en) 2011-01-25
HUP0002474A2 (hu) 2000-10-28
RU2242515C2 (ru) 2004-12-20
ZA985500B (en) 1999-12-24
JP2002510211A (ja) 2002-04-02
HU228845B1 (en) 2013-06-28
JP4286327B2 (ja) 2009-06-24
US20020054878A1 (en) 2002-05-09
RO120848B1 (ro) 2006-08-30
AR013169A1 (es) 2000-12-13
CZ473599A3 (cs) 2000-06-14
NZ501842A (en) 2002-02-01
NO324992B1 (no) 2008-01-14
JP4371248B2 (ja) 2009-11-25
ATE253116T1 (de) 2003-11-15
BR9810654A (pt) 2005-10-04
SK187599A3 (en) 2001-08-06
US6290957B1 (en) 2001-09-18
WO1999001556A2 (en) 1999-01-14
TR200000206T2 (tr) 2000-07-21
PL194562B1 (pl) 2007-06-29
US6682735B2 (en) 2004-01-27
PL338030A1 (en) 2000-09-25

Similar Documents

Publication Publication Date Title
IS2039B (is) Bætt mótefni gegn IgE og aðferð til endurbóta á fjölpeptíðum
NO20071415L (no) OB-fusjonsproteinpreparater og fremgangsmater
NO985339D0 (no) Humane B-celleantigener og beslektede reagenser
NO20000700D0 (no) Interleukin-18-proteiner samt fremstilling og anvendelse derav
NO20001568L (no) Laserjiggesystem og fremgangsmÕte til bruk for sammenstilling av fagverk
DK0974111T3 (da) Apparat og metode til automatiseret design af proteiner
NO985278D0 (no) Elektromagnetiske-til-akustiske og akustiske-til-elektro-magnetiske forsterkere og fremgangsmÕter for bruk av disse
NO970762L (no) Brönnstrengskjötlokalisator og fremgangsmåte derved
CY2010017I2 (el) Νεα πρωτεϊνη και μεθοδος παρασκευης αυτης
DE69427123D1 (de) Screeningverfahren für katalytische nicht-enzym-polypeptide und-proteine
NO20016243D0 (no) Anti-alfav-beta3-rekombinante humane antistoffer, nukleinsyrer som koder for de samme og fremgangsmåter foranvendelse
IS5525A (is) Innúðabúnaður og aðferð
NO981426D0 (no) Fremgangsmåte og anordning for primær-brönn-sementering
NO994009D0 (no) Gensekvensator og metoder
NO971847D0 (no) Diffusjonsbindingsfremgangsmåte og diffusjonsbindingsapparat
NO976122L (no) AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes
DK0870148T3 (da) Hurtig-til-/fra-kobling og fremgangsmåde og indretning til samling deraf
NO972578L (no) FremgangsmÕte og anordning for forsegling
DK0991666T3 (da) Alfa-1-antitrypsin-præparat og fremgangsmåde til fremstilling heraf
NO971448D0 (no) Anti-Fas rekombinante antistoffer og DNA derfor
IS5156A (is) Aðferð og búnaður til að framkalla þéttlokun
DK0970465T3 (da) Indretning og fremgangsmåde til prosodigenerering til visuel syntese
NO982181D0 (no) Type IX collagen og chimerer
NO905561D0 (no) Proteiner og nukleinsyrer.
DK1707621T3 (da) Muteret bioluminescerende protein og fremgangsmåde til fremstilling af det muterede bioluminiscerende protein